Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins

Inactive Publication Date: 2005-05-26
ARMY MEDICAL RES & MATERIEL COMMAND UNITED STATES AS REPRESENTED BY THE DEPT OF THE
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The invention is directed to the core structures called “Previns” which have an internal QF bond and the ability to inhibit BttxB protease activity. As the tetan

Problems solved by technology

However, Zn-metalloprotease inhibitors, such as angiotensin converting enzyme inhibitors, captopril and phosphoramidon, are not effective inhibitors of Bttxs.
Furthermore, some Zn-chelators are toxic at concentrations necessary to delay the Bttx p

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
  • Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
  • Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins

Examples

Experimental program
Comparison scheme
Effect test

example 1

Endopeptidase Activity Assay

[0110] The toxin was activated immediately prior to use by incubating at 25° C. for 30 minutes in an activation mixture that contained, in a volume of 7.5 μl per digest: 2.4 μg (16 pmol) of toxin, 30 mM NaHEPES buffer, pH 7.3, and 5 mM DTT or TCEP. A substrate peptide mix was prepared that contained 1 nmol of the substrate peptide (VAMP2 55-94), 4% DMSO, 4% Triton X-100, and 80 mM NaHEPES buffer, pH 7.3, per digest. The final reaction mix was made by adding 25 μl of the substrate peptide mix, 4.5 μl of fresh 10 mM DTT, 13 μl H2O or test peptide, and 7.5 μl of activation mixture. The reaction was initiated by incubation at 37° C.. The reaction was stopped by the addition of 1 vol trifluoroacetic acid (TFA) to 0.25%. The samples were clarified by centrifligation.

[0111] In this assay, 16 pmol of BttxB digested 1 nmol of the substrate to completion in less than 45 min. at 37° C..

example 2

Reverse Phase HPLC Analysis of Digestion Products

[0112] Digested peptide products were fractionated by RP-HPLC on a Waters:Bondapak analytical C18 column (3.9 mm×30 cm) attached to Beckman 126 pumps and a model 168 Diode Array Detector, controlled by Beckman System Gold Ver 8.1 software. The solvent system consisted of buffer A (BA; H2O-0.1% TFA) and buffer B (BB; CH3CN-0.1%TFA). The development program consisted of the following: 97% BA, 0-1 min; to 33% BB, 1-30 min; then wash with 97% BB for 5 min, followed by equilibration in 97% BA for 10 min. The flow rate was ml min−1 except during the wash and equilibrium phase where it was 1.5 ml min−1. 75 μl injections were made with a Waters Intelligent Sample Processor (WISP Model 712). The effluent was monitored at dual wavelengths of 205 and 280 nm.

[0113] Initially, digestion products are identified by peptide sequencing using automated Edman-degradation on an ABI 477A protein sequencer attached in-line with a HPLC (ABI model 120A) fo...

example 3

Secondary Structure Predictions

[0114] Secondary structures were predicted by using the nnpredict, and the Gibrat (GOR2) programs. See McCleland, D. G, Rumelhart D. E. In Explorations in Parallel Distributed Processing. vol. 3:318-362. 1988. MIT Press, Cambridge Mass.; Kneller D. G., et al. (1990) J. Mol. Biol. 214:171-182; Garnier, J. et al. (1978) J. Mol. Biol 198;425-443; Garnier J. et al. (1987) J. Mol. Biol. 120:97-120; Garnier, J., et al. (1996) Methods Enzymol. 266:540-553. Helical wheel projections were made using the Antheprot program Ver 4. See Deleage, G., Instit de Biologie et Chimi des Proteins, Lyon, France.

[0115] The Gibrat program predicts that B-I could form an alpha-helical-turn-alpha-helical configuration similar to that of VAMP2. See Table 3. The result that Buforin I may form a secondary structure similar to VAMP2 then suggests that B-I may also form a similar supersecondary structure of a reverse turn with helix bundling similar to VAMP2. See Lebeda, et. al. (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Solubility (mass)aaaaaaaaaa
Biocompatibilityaaaaaaaaaa
Login to view more

Abstract

The compounds of the invention are generally described by the formula:
B1Z*2B3Z*4X*5Q6F7X8X9X10X11   (1),
B1X2X3X4X5Q6F7X8X9X10X11   (2), or
B1Z2B3X4Z5Q6F7Z8X9X10X11   (3)
and the salts, esters, amides, and acyl forms thereof. Each position represented by a letter indicates a single amino acid residue: B is a basic of polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z* is Proline or a polar/large of hydrophobic amino acid or a modified form thereof. As described below, one or more of the peptide linkages between the amino acid residues may be replaced by a peptide linkage mimic. These compounds may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum b and tetanus toxins.

Description

TECHNICAL FIELD [0001] The invention relates to a class of peptide and peptide-like compounds, “Previns” which inhibit the enzymatic activity of Botulinum toxin B and Tetanus neurotoxins and may be used as molecular building blocks for creating compounds which are optimized for inhibiting the protease activity of Botulinum toxin B and Tetanus neurotoxins. BACKGROUND OF THE INVENTION [0002] The Botulinum toxins (Bttxs) are among the most potent toxins to animals, e.g. the LD50 in mice is about 1 ng / kg. Bttxs comprise a family of seven distinct serotypes (A-G). Bttxs are composed of two subunits comprising a 100 kdal nerve-cell targeting heavy chain and a 50 kdal endoproteolytically active light chain. These toxins are Zn-metalloproteases and contain a Zn-protein binding motif HEXXH. [0003] However, Zn-metalloprotease inhibitors, such as angiotensin converting enzyme inhibitors, captopril and phosphoramidon, are not effective inhibitors of Bttxs. Although Zn-chelators inhibit Bttx pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/53A61K38/00A61K38/55A61P31/04A61P39/02A61P43/00C07K7/06C07K7/08C07K7/22C07K11/00C07K14/81C07K16/38C12N1/15C12N1/19C12N1/21C12N5/10C12N15/09C12P21/02G01N33/569
CPCA61K38/00C07K7/06C07K14/8146C07K7/22C07K7/08A61P31/04A61P39/02A61P43/00
Inventor GORDON, RICHARDMOORAD, DEBORAHDOCTOR, BHUPENDRAGARCIA, GREGORY
Owner ARMY MEDICAL RES & MATERIEL COMMAND UNITED STATES AS REPRESENTED BY THE DEPT OF THE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap